Cochrane review: Nicotine e‑cigarettes outperform NRT for quitting smoking

On 26 August 2026 Cochrane published an update of its living systematic review on electronic cigarettes for smoking cessation. The announcement reports that the update pooled 80 randomized controlled trials including 29,861 participants and concluded that regulated nicotine‑containing e‑cigarettes increased the likelihood of sustained abstinence at six months or longer compared with nicotine‑replacement therapy (NRT) such as patches or gum. Cochrane summarised the absolute effect as approximately four additional quitters per 100 people using nicotine e‑cigarettes compared with NRT.

The release names Dr Jamie Hartmann‑Boyce (University of Massachusetts Amherst) as senior author and Dr Nicola Lindson (University of Oxford) as lead author. Both are cited in the Cochrane statement as urging caution: while nicotine e‑cigarettes are probably less harmful than combustible tobacco, the evidence on long‑term health outcomes remains limited and the reported benefit applies to regulated devices tested in trials, not to illicit or unregulated products.

Randomized controlled trials are a high standard for assessing intervention efficacy, and the aggregation of nearly 30,000 participants gives this update substantial statistical power. For clinicians and smoking‑cessation services, the result provides a clearer evidence base that nicotine e‑cigarettes can be more effective than NRT in helping smokers achieve sustained abstinence at six months. That said, the modest absolute increase (roughly four additional quitters per 100) should be interpreted in context: at population level, even small percentage gains can translate into meaningful reductions in smoking‑related disease, but individual treatment decisions must account for patient preferences, comorbidities and potential risks.

From a public‑health perspective, the result could shift the calculus of cessation strategies, especially in settings where NRT uptake has been limited. However, any policy change must weigh the cessation benefits against broader concerns about youth uptake, dual use, and the long‑term safety profile of vaping products.

Cochrane’s statement underlines several limitations. The finding is specific to regulated nicotine e‑cigarettes as used in the trials; it does not extend to black‑market or tampered devices, which may have different risk profiles. Additionally, the follow‑up durations in the included RCTs are limited: while six‑month and 12‑month abstinence rates are commonly reported, longer‑term safety data — for example on chronic respiratory and cardiovascular outcomes decades after exposure — remain sparse.

The evidence base is also heterogeneous. Trials varied in terms of geographic setting, the type of e‑cigarette devices and nicotine formulations used, and the provision of behavioural support alongside the devices. That heterogeneity makes it harder to isolate the relative contribution of the product itself versus the counselling component. Cochrane therefore calls for longer and more comprehensive studies to better characterise both effectiveness and safety over time.

National and specialist media broadly reported the Cochrane update, and clinical reactions were cautious. Austrian public broadcaster ORF summarised the findings and quoted pulmonologist Lukasz Antoniewicz (MedUni Wien), who warned against uncritical endorsement of e‑cigarettes and pointed to risks such as persistent nicotine dependence and potential cardiopulmonary effects. Similar caution was expressed by pulmonology groups and several professional societies, which have historically emphasised the need for a balanced approach that protects youth and non‑smokers while offering pragmatic tools for adult smokers seeking to quit.

International outlets such as Euronews echoed the dual message: a statistically robust signal for higher cessation success with nicotine e‑cigarettes, paired with a reminder that long‑term harms and broader population effects—particularly among young people—are not fully understood. These balanced media framings reflect the scientific nuance emphasised by the Cochrane authors.

Regulators face immediate choices. One policy path is to enable controlled access to regulated nicotine e‑cigarettes as a cessation aid—potentially through medical prescriptions, quality standards and age restrictions—so that adults seeking to quit have a supervised option shown to increase quit rates. Another path would prioritise prevention of initiation among youth by imposing stricter marketing, flavour, and packaging controls, or by keeping access tightly regulated via pharmacies and healthcare providers.

Cochrane’s caveat about illicit products is particularly relevant for regulators: ensuring a legal market with quality controls could help avoid harms from unregulated devices, but it requires effective enforcement and clear standards. Policy decisions will therefore depend on how authorities balance measurable cessation benefits for adult smokers with the imperative to protect young people and non‑smokers from starting nicotine use.

Key unanswered questions remain. Long‑term safety data beyond the usual 12‑month trial follow‑ups are scarce, and prospective cohort studies or extended RCT follow‑ups will be needed to assess chronic health effects. Researchers also need to clarify which device types, nicotine concentrations and behavioural support models deliver the best outcomes, and whether benefits persist when e‑cigarettes are used outside of clinical trial settings.

Finally, population‑level surveillance will be essential to monitor unintended consequences: rates of youth initiation, dual use with combustible cigarettes, and the evolution of product markets. Until such data accumulate, clinicians and policymakers must navigate a nuanced landscape where an intervention shows increased cessation efficacy but where longer‑term safety and wider societal impacts are not yet fully defined.